Rapid Optimization News Today

1. Higher doses of guideline-medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission were associated with a reduction in 180-day heart failure (HF) readmission, all-cause death, and quality of life (QOL) at 90 days. 2. Patients in high-intensity care (HIC) with higher GDMT doses at week 2 also had

Conclusions could not be made regarding whether lower risk was associated with improvement in heart failure or if the success of optimal medications led to better clinical outcomes.

Heart failure is the greatest health risk facing our aging population. Governments can help prevent premature death and ‘add life to our years’ with immediate action and investment in accessible diagnostics.

There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. Researchers have found in a new study...

Ramping up medication doses quickly after being hospitalized for acute heart failure resulted in a lower risk of dying or being readmitted for heart failure within the first six months after discharge, compared to usual care, according to a featured science research presentation today at the American Heart Association's Scientific Sessions 2022.

An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.

DURHAM, N.C., Oct. 13, 2022 /PRNewswire/ -- Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimizatio...